University of California, Irvine

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, Irvine sits in the top decile of US sponsors by registered trial count (#96 of 15,742 sponsors by registered trial count).

368 total trials 74 currently recruiting 228 completed early-phase tilt top decile by trial count

University of California, Irvine: 368 sponsored US clinical trials, 74 recruiting.

University of California, Irvine sponsors 368 registered US clinical trials on ClinicalTrials.gov, 74 of them currently recruiting, and 228 completed. 27 of these trials are in Phase 3-4 (later-stage) and 92 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cancer, with 6 trials.

Top-decile sponsor footprint

University of California, Irvine ranks in the top decile of sponsors by registered trial count (#96 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 61/100

228 of 258 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

368 total, page 7 of 8

COMPLETED

Robotic-assisted Laparoscopic Sacrocolpopexy

NCT00581334

COMPLETED Phase 1

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

NCT00585650

COMPLETED Phase 1

Effects of PRK 124 Lotion in Acne Rosacea

NCT00580723

COMPLETED Phase 1

Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks: Comparison of 577 nm Versus 595 nm Wavelengths

NCT00573729

COMPLETED

Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients

NCT00581295

COMPLETED NA

LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis

NCT00573365

COMPLETED Phase 1

Fractional Resurfacing Device for Treatment of Acne Scarring

NCT00585286

COMPLETED

Molecular Urine Tests for Prostate Cancer

NCT00581516

COMPLETED

Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.

NCT00556309

COMPLETED

A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging

NCT00556114

COMPLETED NA

Evaluation of Endostapled Anastomoses for Laparoscopic Gastric Bypass (EEA-LGB)

NCT00254072

COMPLETED

Mitochondria and Metabolic Syndrome in a Southern California Chinese Cohort

NCT00786721

COMPLETED NA

Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks

NCT00585247

TERMINATED NA

Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis

NCT00610467

COMPLETED NA

Robotics For Rehabilitation Therapy: Functional Versus Individual Joint Training

NCT01050231

COMPLETED NA

Muscle Pressure in the Flank Position

NCT00395980

COMPLETED NA

Evaluation of the Candela 1064nm:Nd:YAG Laser for Skin Tightening

NCT00585715

COMPLETED

Mitochondria Inborn Errors of Metabolism and ANT Defects in Mitochondria Diseases

NCT00786539

COMPLETED Phase 1

The Reinforcing Mechanisms of Smoking in Adult ADHD

NCT00573859

COMPLETED Phase 2

A Randomized Multicenter Clinical Study On the High Vacuum Body Cavity Drainage System Following Open Heart Surgery

NCT00581399

TERMINATED Phase 1

Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy

NCT00571116

COMPLETED Phase 2

Beta-hCG + Erythropoietin in Acute Stroke

NCT00362414

COMPLETED NA

Effectiveness of Cranberry Ingestion on Bacterial Adhesion: An Adjunct Study

NCT00506025

TERMINATED Phase 2

Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab

NCT00319839

TERMINATED NA

Factors Predicting Response to Shunting in Normal Pressure Hydrocephalus

NCT00613886

COMPLETED

Monitoring Functional Variation in the Breast During Menstrual Cycle by Using Diffuse Optical Spectroscopy

NCT00540306

COMPLETED NA

Brain Dopamine Function in Adults With ADHD

NCT00580814

COMPLETED NA

Understanding and Improving Diabetes Care for Ethnic Minorities

NCT01123239

TERMINATED NA

Traditional vs. Graft-augmented Posterior Colporrhaphy

NCT00581594

COMPLETED

Chart Review of Laparoscopic Radical Cystectomy

NCT00393601

COMPLETED Phase 2

Neoadjuvant Treatment of Breast Cancer

NCT00254592

COMPLETED

Neurological Surgery & Affiliated Services De-Identified Clinical Outcomes Database

NCT00593411

COMPLETED NA

Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains

NCT00556946

COMPLETED NA

Nicotine and Behavior in Adult ADHD

NCT00573248

COMPLETED Phase 1

Resveratrol for Patients With Colon Cancer

NCT00256334

COMPLETED

Optical Coherence Tomography of the Gastrointestinal Tract

NCT00579748

TERMINATED Phase 2

Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma

NCT00256269

TERMINATED

UCI 03-72 Prostate Cancer Detection by Serum Proteomic Profiling

NCT00355758

TERMINATED Phase 2

Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer

NCT00256308

TERMINATED Phase 2

Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer

NCT04039867

COMPLETED

Does Antenatal Fetal Head Circumference Predict Anal Sphincter Injury, a Prospective Study

NCT00580879

TERMINATED Phase 2

Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma

NCT00256321

COMPLETED NA

Telephone Counseling or Standard Care in Patients Who Have Completed Treatment for Stages I, II, or III Cervical Cancer

NCT00086242

COMPLETED NA

FloSeal Tubeless Exit Versus Cope Loop Nephrostomy Versus Fascial Stitch Following Percutaneous Nephrolithotripsy

NCT00360477

COMPLETED

Evaluation of Pre-dose and Post-dose Anti-factor Xa Levels With Enoxaparin Use During Pregnancy

NCT00319176

COMPLETED Phase 2

Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer

NCT00257348

COMPLETED Phase 1

Optical Clearing of the Skin in Conjunction With Laser Treatments

NCT00580736

COMPLETED Phase 1

Cutaneous Effects of Cryogen Spray Cooling

NCT00581568

COMPLETED Phase 2

Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma

NCT00257816

COMPLETED Phase 2

Trial of Ropinirole in Motor Recovery After Stroke

NCT00221390

← Previous Page 7 of 8 Next →

Phase Distribution

PhaseTrial count
Phase 1 46
Phase 2 46
Phase 3 6
Phase 4 21

What is open in the University of California, Irvine pipeline

74 recruiting of 368 indexed (20% open); 228 completed (62%).

Phase mix: 27 late (III/IV) vs 92 early (I/II) (early-phase heavy).

Top condition: Cancer (6 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, Irvine: open-pipeline peers nationwide

Peers matched on 368 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

University of California, Irvine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 0%5%10%15%20%25% Total trials Recruiting share University of California, IrvineNorthwell HealthUNC Lineberger Comprehensive Cancer CenterRoswell Park Cancer InstituteNew York State Psychiatric InstituteUniversity of MiamiEndeavor HealthAcera SurgicalAlign Technology
University of California, Irvine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, Irvine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 368 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

What to do with this University of California, Irvine page

368 registered trials is a research-attention snapshot, not an endorsement of University of California, Irvine or any single study.

  • 74 of University of California, Irvine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cancer is the condition University of California, Irvine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, Irvine pipeline card: 368 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.